Our mission centers on advancing treatments for diabetes mellitus and diabetic foot syndrome while fostering collaboration with biotech and diagnostic firms worldwide: Dr. Mehmet Ali Soylemez of Söylemez Investment

Dr. Söylemez’s pioneering research has led to the widespread use of procalcitonin as a diagnostic biomarker for diabetes mellitus and diabetic foot syndrome.

Dr. Mehmet Ali Soylemez, the founder and Managing Director of Söylemez Investment, is dedicated to driving technological innovation across various industries, particularly in healthcare. Committed to continuous improvement, Söylemez Investment aims to redefine possibilities, promote collaboration, and make a lasting impact in healthcare and beyond.

Dr. Söylemez established Söylemez Investment with a bold vision to advance critical technologies across industries. His passion for collaboration and improving diabetic treatments has earned the company recognition, including the esteemed Innovation Excellence Awards. Besides his entrepreneurial endeavors, Dr. Söylemez is a distinguished Medical Doctor and Scientist, with expertise spanning Clinical Genetics, General Surgery, and Medical Physiology. His groundbreaking research has significantly influenced healthcare, particularly in the diagnosis and management of Diabetes Mellitus and Diabetic Foot Syndrome.

One of Dr. Söylemez’s notable achievements is the identification of the biomarker procalcitonin in diabetes mellitus and diabetic foot syndrome.

“This breakthrough has revolutionized our understanding of these conditions and led to more effective treatments. Our research has resulted in approximately 40 peer-reviewed publications on procalcitonin as a biomarker tool, highlighting its superiority over traditional diagnostics like HgbA1c. Procalcitonin enables faster and more successful treatment by identifying patients at risk of complications early on,” said Dr. Söylemez.

Söylemez Investment is driven by ethical principles, with a focus on respecting human values and clients’ needs. Dr. Mehmet Söylemez emphasizes the importance of designing individualized diagnostic treatment plans to optimize outcomes for diabetic patients. “Our mission centers on advancing treatments for diabetes mellitus and diabetic foot syndrome while fostering collaboration with biotech and diagnostic firms worldwide,” said Dr. Söylemez.

Dr. Söylemez’s pioneering research has led to the widespread use of procalcitonin as a diagnostic biomarker for diabetes mellitus and diabetic foot syndrome. To safeguard his intellectual property, Söylemez Investment has submitted patent applications to the United States Patent and Trademark Office (USPTO) for the following two inventions related to diagnostic biomarkers. These patents aim to secure Söylemez Investment’s position in the US market and support its long-term strategic vision of evolving with advancements in diagnostic and preventive healthcare.

1. Titled, “Procalcitonin Gene Expression As a Precise Biomarker Of Aging Process,” with patent No: US 20130252254 A1 USPTO (United States Patent And Trademark OFFICE).

2. Titled “Diagnosis And Complication Risk Assessment Of Pancreatic Diabetes Using Procalcitonin” with patent No: US 20110263438 A1 USPTO.

Moreover, Dr. Söylemez is the rightful owner of the EUROPEAN patent for this groundbreaking invention, titled of Pancreatic Diabetes in Patients with Normal Blood Leukocyte Counts Using Procalcitonin. This patented invention is registered with the European Patent Office (EPO) under registration number EP2626704 B1, further highlighting the significance and uniqueness of his work. This patent is also protected within three national registries, including the United Kingdom, Sweden, and Turkey.

“I envision that the future of diagnostic and preventive healthcare advancements will rely on diagnostic biomarkers and molecular genetics. Soylemez Investment must be prepared to evolve and adapt to these market changes in the next 5-10 years,” concluded Dr. Soylemez.

Put simply, Dr. Söylemez’s visionary leadership and innovative research have propelled Söylemez Investment to the forefront of technological innovation in healthcare. His commitment to ethical innovation and dedication to improving diabetic treatments demonstrate the company’s potential to make a significant impact in the healthcare industry. With ongoing efforts to patent breakthrough technologies and adapt to market changes, Söylemez Investment is poised to shape the future of healthcare for years to come.

“Our research has resulted in approximately 40 peer-reviewed publications on procalcitonin as a biomarker tool, highlighting its superiority over traditional diagnostics like HgbA1c. Procalcitonin enables faster and more successful treatment by identifying patients at risk of complications early on.”

“I envision that the future of diagnostic and preventive healthcare advancements will rely on diagnostic biomarkers and molecular genetics. Soylemez Investment must be prepared to evolve and adapt to these market changes in the next 5-10 years.”